Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Medtronic’s Valiant Captivia shows safety and efficacy in new trial

Medtronic’s Valiant Captivia shows safety and efficacy in new trial

23rd September 2016

Medtronic has announced the results of a new clinical trial demonstrating the benefits of its Valiant Captivia thoracic stent graft system.

The device has demonstrated its safety and efficacy at three years in acute complicated type B aortic dissection patients, with freedom from all-cause mortality evaluated at 79.4 percent, and freedom from dissection-related mortality recorded at 90 percent.

No post-index procedure ruptures or conversions were seen, underlining the fact that this thoracic endovascular aortic repair method is a safe and effective means of treating this form of complex aortic dissection.

Daveen Chopra, vice-president and general manager of Medtronic's aortic business, said: "The Valiant line of technology leverages decades of clinical experience in continuing to treat thoracic disease and has been used to treat more than 75,000 patients."

Acute aortic dissections occur when the inner layer of the aorta tears, resulting in blood leakage that causes the inner and middle layers of the aorta to separate.

This can result in aorta rupture or malperfusion of the vessels originating from the dissected aorta, leading to high morbidity and mortality.

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801825662-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.